AstraZeneca data at WCLC advance ambition to have an AZ med for over half of patients treated for lung cancer by 2030 • BusinessMirror
New data across diverse innovative therapeutic options showcase commitment to redefining lung cancer outcomes AstraZeneca advances its lung cancer portfolio and pipeline at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC), held in Singapore from 9 to 12 September 2023. More than 40 abstracts featured eight
Source: businessmirror.com.ph
